Patents Assigned to Ayala Pharmaceuticals Inc.
  • Publication number: 20230381196
    Abstract: The present invention provides methods of treating or suppressing Adenoid Cystic Carcinoma (ACC) or inhibiting ACC tumor growth in subjects by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (III) or prodrugs thereof.
    Type: Application
    Filed: September 17, 2021
    Publication date: November 30, 2023
    Applicant: Ayala Pharmaceuticals Inc.
    Inventors: Dana GELBAUM, Jeffrey KAUFMAN, Joel KAYE
  • Publication number: 20230108536
    Abstract: The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I) wherein: R1 each is independently F, Cl, Br, I, OCH3, CN or NO2; R2 each is independently identical or different C1-C5 alkyl; n1 is an integer between 1 and 5; and n2 is an integer between 1 and 4.
    Type: Application
    Filed: February 16, 2021
    Publication date: April 6, 2023
    Applicant: Ayala Pharmaceuticals Inc.
    Inventors: Christopher M. CIMARUSTI, Anandkumar Madanlal LAHOTI, Madan Raja Gopal Reddy DARAM
  • Publication number: 20230018980
    Abstract: The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; optionally in combination with an additional cancer therapeutic agent, and methods of use thereof for treating proliferative diseases and disorders such as Desmoid tumors.
    Type: Application
    Filed: September 12, 2022
    Publication date: January 19, 2023
    Applicants: Bristol-Myers Squibb Company, Ayala Pharmaceuticals Inc.
    Inventors: Bruce S. FISCHER, Gaurav Bajaj, Matti Davis, Joel Kaye
  • Publication number: 20220339162
    Abstract: The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; optionally in combination with an additional cancer therapeutic agent, and methods of use thereof for treating proliferative diseases and disorders such as Desmoid tumors.
    Type: Application
    Filed: July 5, 2022
    Publication date: October 27, 2022
    Applicant: Ayala Pharmaceuticals Inc.
    Inventors: Matti DAVIS, Joel KAYE, Rami RAUCH
  • Publication number: 20220288088
    Abstract: The present invention provides methods of use for compositions comprising an immunotherapeutic such as chimeric antigen receptor T cells (CAR-T cells), and specifically those that target a tumor antigen cleaved by gamma secretase, in combination with bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; for treating lymphomas.
    Type: Application
    Filed: May 17, 2022
    Publication date: September 15, 2022
    Applicant: Ayala Pharmaceuticals Inc.
    Inventors: David SIDRANSKY, Amnon PELED
  • Publication number: 20220241294
    Abstract: The present invention provides methods of reducing tumor size, suppressing or inhibiting tumor growth, or prolonging progression-free survival or overall survival in subjects having Notch-activated breast cancer by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (III): or prodrugs thereof, alone or in combination with a composition comprising a cytotoxic agent. Notch-activated breast cancer may be determined by a) Notch-activating genetic alterations in one or more Notch genes, b) overexpression of one or more Notch-regulated genes, c) overexpression of one or more Notch proteins or Notch-regulated proteins, or a combination thereof.
    Type: Application
    Filed: May 14, 2020
    Publication date: August 4, 2022
    Applicant: Ayala Pharmaceuticals Inc.
    Inventor: Matti DAVIS
  • Publication number: 20210379079
    Abstract: The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; (I), in combination with an ani-CD20 agent or other anti-CD20 therapy, and methods of use thereof for treating diseases and disorders such as cancer.
    Type: Application
    Filed: May 6, 2019
    Publication date: December 9, 2021
    Applicant: Ayala Pharmaceuticals Inc.
    Inventor: Roni MAMLUK
  • Publication number: 20210244745
    Abstract: The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; in combination with an additional cancer therapeutic agent, and methods of use thereof for treating diseases and disorders such as cancer.
    Type: Application
    Filed: May 5, 2019
    Publication date: August 12, 2021
    Applicant: Ayala Pharmaceuticals Inc.
    Inventor: Matti DAVIS
  • Publication number: 20210220372
    Abstract: The present invention provides methods of use for compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; for treating diseases and disorders such as cancer.
    Type: Application
    Filed: May 15, 2019
    Publication date: July 22, 2021
    Applicants: Bristol-Myers Squibb Company, Ayala Pharmaceuticals Inc.
    Inventors: Bruce S. FISCHER, Gaurav BAJAJ, David SIDRANSKY
  • Publication number: 20210040050
    Abstract: The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; in combination with an additional cancer therapeutic agent, and methods of use thereof for treating diseases and disorders such as cancer.
    Type: Application
    Filed: October 22, 2020
    Publication date: February 11, 2021
    Applicant: Ayala Pharmaceuticals Inc.
    Inventor: Matti Davis
  • Publication number: 20200085839
    Abstract: The present invention provides methods of use for compositions comprising an immunotherapeutic such as chimeric antigen receptor T cells (CAR-T cells), and specifically those that target a tumor antigen cleaved by gamma secretase, in combination with bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; for treating lymphomas.
    Type: Application
    Filed: September 24, 2019
    Publication date: March 19, 2020
    Applicant: Ayala Pharmaceuticals Inc.
    Inventors: David SIDRANSKY, Amnon PELED
  • Publication number: 20200022990
    Abstract: The present invention provides methods of treating or suppressing Adenoid Cystic Carcinoma (ACC) or inhibiting ACC tumor growth in subjects by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (III) or prodrugs thereof.
    Type: Application
    Filed: September 27, 2019
    Publication date: January 23, 2020
    Applicant: Ayala Pharmaceuticals Inc.
    Inventor: David SIDRANSKY